• SPX
  • $5,959.27
  • 0.18 %
  • $10.56
  • DJI
  • $44,235.87
  • 0.83 %
  • $365.51
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,977.78
  • 0.03 %
  • $5.36
OncoSec Medical Incorporated (ONCS) Stock Price, News & Analysis

OncoSec Medical Incorporated (ONCS) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.25
Day's range
$0.4
50-day range
$0.18
Day's range
$1.31
  • Country: US
  • ISIN: US68234L3069
52 wk range
$0.18
Day's range
$20.46
  • CEO: Dr. Robert H. Arch Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -59.80
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (ONCS)
  • Company OncoSec Medical Incorporated
  • Price $0.28
  • Changes Percentage (31.87%)
  • Change $0.07
  • Day Low $0.25
  • Day High $0.40
  • Year High $20.46

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 12/11/2020
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$20.31
  • Trailing P/E Ratio -0.013648449039882
  • Forward P/E Ratio -0.013648449039882
  • P/E Growth -0.013648449039882
  • Net Income $-34,179,634

Income Statement

Quarterly

Annual

Latest News of ONCS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

OncoSec Medical Incorporated Frequently Asked Questions

  • What were the earnings of ONCS in the last quarter?

    In the last quarter OncoSec Medical Incorporated earnings were on Thursday, December, 15th. The OncoSec Medical Incorporated maker reported -$4.50 EPS for the quarter, beating analysts' consensus estimates of -$4.90 by $0.40.

  • What is the OncoSec Medical Incorporated stock price today?

    Today's price of OncoSec Medical Incorporated is $0.28 — it has increased by +31.87% in the past 24 hours. Watch OncoSec Medical Incorporated stock price performance more closely on the chart.

  • Does OncoSec Medical Incorporated release reports?

    Yes, you can track OncoSec Medical Incorporated's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the OncoSec Medical Incorporated stock forecast?

    Watch the OncoSec Medical Incorporated chart and read a more detailed OncoSec Medical Incorporated stock forecast to see what analysts suggest you do with its shares.

  • What is OncoSec Medical Incorporated stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by OncoSec Medical Incorporated stock ticker.

  • How to buy OncoSec Medical Incorporated stocks?

    Like other stocks, ONCS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is OncoSec Medical Incorporated's EBITDA?

    OncoSec Medical Incorporated measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in OncoSec Medical Incorporated’s financial statements.

  • What is the OncoSec Medical Incorporated's net income ratio for the financial year 2022?

    The net income ratio for the financial year 2022 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in OncoSec Medical Incorporated stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including OncoSec Medical Incorporated's financials relevant news, and technical analysis. OncoSec Medical Incorporated's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for OncoSec Medical Incorporated stock currently indicates a “sell” signal. For more insights, review OncoSec Medical Incorporated’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.